WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug shows promise in rare blood cancer
Disease control CompletedThis study tested the drug carfilzomib in 7 people with Waldenström's macroglobulinemia, a rare blood cancer, that had returned after previous treatment. The goal was to see if the drug could shrink tumors and control the cancer. Carfilzomib works by blocking a protein that helps…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 16, 2026 21:07 UTC
-
New hope for rare blood cancer patients: lenalidomide dose trial completed
Disease control CompletedThis study tested different doses of the drug lenalidomide in 17 people with Waldenstrom Macroglobulinemia, a rare blood cancer, whose disease had come back or stopped responding to prior treatments. The main goal was to find a safe dose by tracking side effects. Researchers also…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Stem cell transplant study seeks best way to prevent immune attack
Disease control CompletedThis study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for lymphoma patients who Can't tolerate standard drugs
Disease control CompletedThis study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had bad side effects from similar drugs like ibrutinib or acalabrutinib. The main goal was to see if zanubrutinib causes…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Gut bacteria drug shows promise against blood disorder
Disease control CompletedThis early-phase study tested whether the oral antibiotic rifaximin can reduce abnormal proteins in people with monoclonal gammopathy, a condition that can lead to blood cancers. Fifty adults with different types of gammopathy took the drug to see if it lowered their immunoglobul…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
New drug candidate BR101801 tested in patients with advanced blood cancers
Disease control CompletedThis early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study was completed, but results are no…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
Vaccine response checked in blood cancer patients
Knowledge-focused CompletedThis study looked at whether the COVID-19 vaccine triggers a strong immune response in people with multiple myeloma or Waldenstrom's macroglobulinemia, two types of blood cancer. About 146 adults took part, and researchers measured their antibody levels 28 days after the final va…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:25 UTC
-
Blood and urine tests may replace painful bone marrow biopsies for Waldenström's patients
Knowledge-focused CompletedThis study looked at whether blood or urine tests can accurately detect genetic mutations linked to Waldenström's macroglobulinemia (WM) and a related condition, IgM-MGUS. Researchers compared results from these non-invasive tests with the standard bone marrow biopsy in 300 parti…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:08 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 05, 2026 12:09 UTC